{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:20Z","timestamp":1787008940910,"version":"build-2736575974"},"reference-count":112,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals U.S.A., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As the prevalence of inflammatory bowel disease (IBD) rises rapidly among older adults, gastroenterologists and other health care providers increasingly face challenges in managing age-related comorbidities, polypharmacy, and functional impairments such as frailty and sarcopenia. This narrative review proposes a dual approach to management by optimizing care for patients aged &amp;gt;60\u2009years while promoting the healthy aging of those aged 40-60\u2009years. For patients aged &amp;gt;60\u2009years, we emphasize prescribing effective corticosteroid-sparing medications to control inflammation, conducting medication reconciliations to assess appropriateness and drug interactions, and evaluating baseline hepatic and renal function for necessary dose adjustments. For patients aged 40-60\u2009years, we advise regular screening and nutritional counseling to delay the onset of age-related comorbidities and recommend targeting endoscopic remission to modify the disease course and reduce complications and disability later in life. Given that patients with IBD receiving long-term immunosuppression are at increased risk of infections, adherence to age-appropriate vaccination schedules is also recommended. A proactive and personalized approach to disease management has the potential to optimize quality of life for older adults with IBD.<\/jats:p>","DOI":"10.1093\/ibd\/izag122","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:39:16Z","timestamp":1783532356000},"source":"Crossref","is-referenced-by-count":1,"title":["Inflammatory bowel disease in the aging population"],"prefix":"10.1093","author":[{"given":"Adam S","family":"Faye","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, NYU Langone Health , New York, NY 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-1236","authenticated-orcid":false,"given":"Bharati","family":"Kochar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]},{"name":"The Mongan Institute Clinical & Translational Epidemiology Unit, , Boston, MA 02114,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center and Department of Pharmacy, University of Chicago Medicine , Chicago, IL 60637,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Gift","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc , Cambridge, MA 02142,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra J","family":"Kamp","sequence":"additional","affiliation":[{"name":"Department of Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington , Seattle, WA 98195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L","family":"Rider","sequence":"additional","affiliation":[{"name":"Department of Health Systems and Implementation Science, Virginia Tech Carilion School of Medicine , Roanoke, VA 24016,","place":["United States"]},{"name":"Section of Allergy and Immunology, Department of Pediatrics, Carilion Clinic , Roanoke, VA 24018,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary , Calgary, AB T2N 4Z6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070813391354100_izag122-B1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"2026070813391354100_izag122-B2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/s0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2026070813391354100_izag122-B3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis","volume":"119","author":"Coward","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026070813391354100_izag122-B6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2026.01.009","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease across nine epidemiologic stage 3 nations","author":"Coward","year":"2026","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1093\/ibd\/izz092","article-title":"Comparative incidence of inflammatory bowel disease in different age groups in the United States","volume":"25","author":"Keyashian","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B10","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1093\/jcag\/gwad013","article-title":"The 2023 impact of inflammatory bowel disease in Canada: special populations-IBD in seniors","volume":"6","author":"Shaffer","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026070813391354100_izag122-B11","first-page":"592","article-title":"Management considerations for the older adult with inflammatory bowel disease","volume":"19","author":"Axenfeld","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026070813391354100_izag122-B12","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.14309\/ajg.0000000000003641.03","article-title":"Practical advice for the management of older adults with inflammatory bowel disease","volume":"120","author":"Kochar","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: an expanding universe","volume":"186","author":"L\u00f3pez-Ot\u00edn","year":"2023","journal-title":"Cell"},{"key":"2026070813391354100_izag122-B14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/ibd\/izab039","article-title":"Aging and IBD: a new challenge for clinicians and researchers","volume":"28","author":"Faye","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12016-021-08899-6","article-title":"Immunology of aging: the birth of inflammaging","volume":"64","author":"Fulop","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026070813391354100_izag122-B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12979-020-00213-w","article-title":"Gut microbiota as the key controllers of \"healthy\" aging of elderly people","volume":"18","author":"Ragonnaud","year":"2021","journal-title":"Immun Ageing"},{"key":"2026070813391354100_izag122-B17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10620-021-06990-8","article-title":"Inflammatory bowel disease patients who respond to treatment with anti-tumor necrosis factor agents demonstrate improvement in pre-treatment frailty","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/cells11030359","article-title":"Interconnections between inflammageing and immunosenescence during ageing","volume":"11","author":"Teissier","year":"2022","journal-title":"Cells"},{"key":"2026070813391354100_izag122-B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of age-related thymic involution to immunosenescence and inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun Ageing"},{"key":"2026070813391354100_izag122-B20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121314","article-title":"Immunosenescence: aging and immune system decline","volume":"12","author":"Goyani","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026070813391354100_izag122-B21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s10875-010-9448-8","article-title":"Impaired functions of peripheral blood monocyte subpopulations in aged humans","volume":"30","author":"Nyugen","year":"2010","journal-title":"J Clin Immunol"},{"key":"2026070813391354100_izag122-B22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.4049\/jimmunol.178.2.970","article-title":"Age-associated defect in human TLR-1\/2 function","volume":"178","author":"van Duin","year":"2007","journal-title":"J Immunol"},{"key":"2026070813391354100_izag122-B23","doi-asserted-by":"publisher","first-page":"e13701","DOI":"10.1111\/acel.13701","article-title":"Production of MHCII-expressing classical monocytes increases during aging in mice and humans","volume":"21","author":"Barman","year":"2022","journal-title":"Aging Cell"},{"key":"2026070813391354100_izag122-B24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3389\/fmicb.2016.02111","article-title":"Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection","volume":"7","author":"Tu","year":"2016","journal-title":"Front Microbiol"},{"key":"2026070813391354100_izag122-B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol"},{"key":"2026070813391354100_izag122-B26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s10620-012-2517-5","article-title":"Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease","volume":"58","author":"Matsumoto","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/meg.0000000000001768","article-title":"Gastroenterologists\u2019 preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey","volume":"32","author":"Chan","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B28","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/imj.15928","article-title":"Clinical outcomes amongst elderly patients with inflammatory bowel disease","volume":"53","author":"Sivanathan","year":"2023","journal-title":"Intern Med J"},{"key":"2026070813391354100_izag122-B29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/mcg.0000000000001557","article-title":"Older adult patients use more aminosalicylate monotherapy compared with younger patients with inflammatory bowel disease: TARGET-IBD","volume":"56","author":"Barnes","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"2026070813391354100_izag122-B30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.dld.2024.02.002","article-title":"Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study","volume":"56","author":"Anisdahl","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026070813391354100_izag122-B31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ibd\/izab052","article-title":"Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases","volume":"27","author":"Kochar","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B32","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/s2666-7568(22)00060-5","article-title":"Is it time to include older adults in inflammatory bowel disease trials? A call for action","volume":"3","author":"Vieujean","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"2026070813391354100_izag122-B33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/apt.13294","article-title":"Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease","volume":"42","author":"Lobat\u00f3n","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10620-022-07770-8","article-title":"Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn\u2019s disease patients","volume":"68","author":"Gebeyehu","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/meg.0000000000002436","article-title":"Safety and effectiveness of ustekinumab in elderly Crohn\u2019s disease patients","volume":"34","author":"Fiske","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/apt.16923","article-title":"Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study","volume":"56","author":"Pugliese","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cgh.2020.04.070","article-title":"Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials","volume":"19","author":"Cheng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B38","doi-asserted-by":"publisher","first-page":"e2234200","DOI":"10.1001\/jamanetworkopen.2022.34200","article-title":"Comparative outcomes and safety of vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases","volume":"5","author":"Singh","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026070813391354100_izag122-B39","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1093\/ibd\/izad305","article-title":"Older adults with inflammatory bowel disease are at higher risk of developing antibodies to infliximab","volume":"30","author":"Faye","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2026070813391354100_izag122-B41","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.15214","article-title":"Early combined immunosuppression may be effective and safe in older patients with Crohn\u2019s disease: post hoc analysis of REACT","volume":"49","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/ecco-jcc\/jjad158","article-title":"Mitigating the risk of tofacitinib-induced adverse events in the elderly population with ulcerative colitis","volume":"18","author":"Viola","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070813391354100_izag122-B44","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.14309\/01.ajg.0000995852.39535.01","article-title":"Safety of upadacitinib in older patients with ulcerative colitis: a real-world experience","volume":"118","author":"Chowla","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131722","article-title":"Efficacy and safety of biological therapies and jak inhibitors in older patients with inflammatory bowel disease","volume":"12","author":"Fries","year":"2023","journal-title":"Cells"},{"key":"2026070813391354100_izag122-B46","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/apt.17520","article-title":"Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study","volume":"58","author":"N\u00f8rg\u00e5rd","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B48","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.14309\/ajg.0000000000002395","article-title":"Preoperative risk factors for adverse events in adults undergoing bowel resection for inflammatory bowel disease: 15-year assessment of the American College of Surgeons National Surgical Quality Improvement Program","volume":"118","author":"Fernandez","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B49","first-page":"263","article-title":"Frailty in patients with inflammatory bowel disease","volume":"17","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026070813391354100_izag122-B50","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070813391354100_izag122-B51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/apt.15821","article-title":"Frailty is independently associated with mortality in 11001 patients with inflammatory bowel diseases","volume":"52","author":"Kochar","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B52","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.cgh.2022.01.001","article-title":"Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B53","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/ibd\/izac242","article-title":"Frail phenotype in patients with inflammatory bowel disease","volume":"29","author":"Salvatori","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B54","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3390\/jcm12072658","article-title":"Reversibility of frail phenotype in patients with inflammatory bowel diseases","volume":"12","author":"Salvatori","year":"2023","journal-title":"J Clin Med"},{"key":"2026070813391354100_izag122-B55","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B56","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/ibd\/izaa327","article-title":"Frailty and risk of serious infections in biologic-treated patients with inflammatory bowel diseases","volume":"27","author":"Singh","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B57","doi-asserted-by":"publisher","first-page":"e240003","DOI":"10.20900\/agmr20240003","article-title":"Sarcopenia as a preoperative risk stratification tool among older adults with inflammatory bowel disease","volume":"6","author":"Minawala","year":"2024","journal-title":"Adv Geriatr Med Res"},{"key":"2026070813391354100_izag122-B58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s11938-022-00389-8","article-title":"Sarcopenia in inflammatory bowel diseases: reviewing past work to pave the path for the future","volume":"20","author":"Faye","year":"2022","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2026070813391354100_izag122-B59","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clnu.2023.05.002","article-title":"Systematic review of sarcopenia in inflammatory bowel disease","volume":"42","author":"Fatani","year":"2023","journal-title":"Clin Nutr"},{"key":"2026070813391354100_izag122-B60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21037\/atm-22-1126","article-title":"Sarcopenia is associated with poor clinical outcomes in patients with inflammatory bowel disease: a prospective cohort study","volume":"10","author":"Liu","year":"2022","journal-title":"Ann Transl Med"},{"key":"2026070813391354100_izag122-B61","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ibd\/izae187","article-title":"Sarcopenia is a risk factor for postoperative complications among older adults with inflammatory bowel disease","volume":"31","author":"Minawala","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.gastrohep.2020.09.002","article-title":"Inflammatory bowel disease and the risk of cardiovascular diseases","volume":"44","author":"Nu\u00f1ez","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B63","doi-asserted-by":"publisher","first-page":"pkab096","DOI":"10.1093\/jncics\/pkab096","article-title":"Associations of inflammatory bowel disease and subsequent cancers in a population-based study of older adults in the united states","volume":"6","author":"Wang","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"2026070813391354100_izag122-B64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/gutjnl-2020-320789","article-title":"Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"2026070813391354100_izag122-B65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/mib.0000000000001099","article-title":"Management of inflammatory bowel disease in the elderly patient: challenges and opportunities","volume":"23","author":"Ananthakrishnan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B66","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/circresaha.111.246876","article-title":"The intersection between aging and cardiovascular disease","volume":"110","author":"North","year":"2012","journal-title":"Circ Res"},{"key":"2026070813391354100_izag122-B67","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/apt.17162","article-title":"Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis","volume":"56","author":"Faye","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070813391354100_izag122-B68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","article-title":"Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis","volume":"12","author":"Sarlos","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026070813391354100_izag122-B70","doi-asserted-by":"publisher","first-page":"e32775","DOI":"10.1097\/md.0000000000032775","article-title":"Inflammatory bowel disease and associated cardiovascular disease outcomes: a systematic review","volume":"102","author":"Jaiswal","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2026070813391354100_izag122-B71","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B72","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","article-title":"Age and cancer risk: a potentially modifiable relationship","volume":"46","author":"White","year":"2014","journal-title":"Am J Prev Med"},{"key":"2026070813391354100_izag122-B73","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.14309\/ajg.0000000000002900","article-title":"A population-based matched cohort study of digestive system cancer incidence and mortality in individuals with and without inflammatory bowel disease","volume":"119","author":"Murthy","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B74","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/ibd\/izac171","article-title":"Risks of melanoma and nonmelanoma skin cancers pre- and post-inflammatory bowel disease diagnosis","volume":"29","author":"Narous","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B75","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B76","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.dld.2024.07.018","article-title":"Small molecules for inflammatory bowel disease and the risk of infection and malignancy: a systematic review and meta-analysis","volume":"56","author":"Chen","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026070813391354100_izag122-B77","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/cancers15020542","article-title":"Therapeutic management of adults with inflammatory bowel disease and malignancies: a clinical challenge","volume":"15","author":"Ferretti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070813391354100_izag122-B78","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032","article-title":"AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: commentary","volume":"22","author":"Axelrad","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.urology.2017.01.030","article-title":"Implications of prostate cancer treatment in men with inflammatory bowel disease","volume":"104","author":"Kirk","year":"2017","journal-title":"Urology"},{"key":"2026070813391354100_izag122-B80","doi-asserted-by":"publisher","first-page":"466","DOI":"10.14740\/jocmr4593","article-title":"Inflammatory bowel disease and patients with mental disorders: what do we know?","volume":"13","author":"Fousekis","year":"2021","journal-title":"J Clin Med Res"},{"key":"2026070813391354100_izag122-B81","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s10620-023-08250-3","article-title":"Prevalence and appropriateness of polypharmacy in older adults with inflammatory bowel diseases","volume":"69","author":"Kochar","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B82","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric adverse effects of corticosteroids","volume":"81","author":"Warrington","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2026070813391354100_izag122-B83","doi-asserted-by":"publisher","first-page":"Cd000296","DOI":"10.1002\/14651858.CD000296.pub4","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","volume":"2015","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070813391354100_izag122-B84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194329","article-title":"Comparative outcomes of budesonide MMX versus prednisolone for ulcerative colitis: results from a British retrospective multi-centre real-world study","volume":"10","author":"Rosiou","year":"2021","journal-title":"J Clin Med"},{"key":"2026070813391354100_izag122-B85","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5217\/ir.2019.00050","article-title":"Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study","volume":"17","author":"Wang","year":"2019","journal-title":"Intest Res"},{"key":"2026070813391354100_izag122-B86","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14309\/ajg.0000000000003036","article-title":"Severe polypharmacy increases risk of hospitalization among older adults with inflammatory bowel disease","volume":"120","author":"Drittel","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B87","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"2026070813391354100_izag122-B88","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/ecco-jcc\/jjae049","article-title":"Chronic kidney disease in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Zadora","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070813391354100_izag122-B89","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors","volume":"21","author":"Rodriguez-Duque","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B90","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf042","article-title":"Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health","volume":"19","author":"Chhibba","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026070813391354100_izag122-B91","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3748\/wjg.v25.i30.4148","article-title":"Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments","volume":"25","author":"Clarke","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2026070813391354100_izag122-B92","doi-asserted-by":"publisher","first-page":"Cd000279","DOI":"10.1002\/14651858.CD000279.pub4","article-title":"Strategies for detecting colon cancer in patients with inflammatory bowel disease","volume":"9","author":"Bye","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070813391354100_izag122-B93","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s10620-018-5056-x","article-title":"Low rates of dermatologic care and skin cancer screening among inflammatory bowel disease patients","volume":"63","author":"Anderson","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026070813391354100_izag122-B94","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cgh.2024.12.011","article-title":"AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review","volume":"23","author":"Caldera","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B95","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/jcp.25001","article-title":"Determinants of muscle and bone aging","volume":"230","author":"Curtis","year":"2015","journal-title":"J Cell Physiol"},{"key":"2026070813391354100_izag122-B96","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.3748\/wjg.v26.i35.5362","article-title":"Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease","volume":"26","author":"K\u00e4rnsund","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2026070813391354100_izag122-B97","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000496935","article-title":"Risk factors for low bone density in inflammatory bowel disease: use of glucocorticoids, low body mass index, and smoking","volume":"37","author":"Even Dar","year":"2019","journal-title":"Dig Dis"},{"key":"2026070813391354100_izag122-B98","doi-asserted-by":"publisher","first-page":"14087","DOI":"10.3748\/wjg.v20.i39.14087","article-title":"Managing osteoporosis in ulcerative colitis: something new?","volume":"20","author":"Piodi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2026070813391354100_izag122-B99","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","article-title":"ACG clinical guideline update: preventive care in inflammatory bowel disease","volume":"120","author":"Farraye","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B100","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/ibd\/izaf204","article-title":"Menopause and inflammatory bowel disease: a systematic review","volume":"31","author":"Kale","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B101","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/jcsm.13341","article-title":"Impact of malnutrition and sarcopenia on quality of life in patients with inflammatory bowel disease: a multicentre study","volume":"14","author":"Zhang","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026070813391354100_izag122-B102","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2023.11.303","article-title":"AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review","volume":"166","author":"Hashash","year":"2024","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izaa097","article-title":"Multidimensional impact of mediterranean diet on IBD patients","volume":"27","author":"Chicco","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026070813391354100_izag122-B104","doi-asserted-by":"publisher","first-page":"536","DOI":"10.20524\/aog.2024.0900","article-title":"Micronutrient deficiencies in older patients with inflammatory bowel disease are not associated with worse adverse clinical outcome rates","volume":"37","author":"Andres","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"2026070813391354100_izag122-B105","doi-asserted-by":"publisher","first-page":"210","DOI":"10.11124\/jbisrir-2016-2296","article-title":"The effectiveness of the teach-back method on adherence and self-management in health education for people with chronic disease: a systematic review","volume":"14","author":"Ha Dinh","year":"2016","journal-title":"JBI Database System Rev Implement Rep"},{"key":"2026070813391354100_izag122-B106","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070813391354100_izag122-B107","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2026070813391354100_izag122-B108","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070813391354100_izag122-B109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","article-title":"Treat to target in Crohn\u2019s disease: a practical guide for clinicians","volume":"30","author":"Srinivasan","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2026070813391354100_izag122-B110","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3748\/wjg.v19.i9.1349","article-title":"Efficacy of the vaccination in inflammatory bowel disease","volume":"19","author":"Carrera","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2026070813391354100_izag122-B111","author":"Cornerstones Health","year":"2025"},{"key":"2026070813391354100_izag122-B112","author":"Crohn\u2019s and Colitis Foundation","year":"2025"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag122\/68721689\/izag122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag122\/68721689\/izag122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:39:18Z","timestamp":1783532358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag122\/8728488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":112,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag122","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"izag122"}}